Kelley Presents at National Institutes of Health

Dr. Mark Kelley, Chief Scientific Officer of Apexian Pharmaceuticals, presented a special seminar at the National Institutes of Health on October 3 on his research on APX3330’s effect on the Ref-1/APE signaling node in cancer and chemotherapy-induced neuropathy. In addressing the National Institute of Environmental Health Sciences, Dr. Kelley discussed the progress of this promising therapy from benchtop to the current phase 1 clinical trial.